Cohance Lifesciences Ltd

NSE: COHANCE · BSE: 543064 · Pharmaceuticals & Biotechnology · 33 announcements

Share price: ₹455.45
Market cap: ₹17,425 Cr
Revenue (annual): ₹2,269 Cr
Net profit (annual): ₹179.2 Cr
P/E (TTM): 164.0×Sector 47.3×
Promoter holding: 57.49%+0.00% QoQ
FII holding: 6.50%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

27 Apr 2026 08:59 IST NSE

Cohance Lifesciences Board Meeting Outcome

Cohance Lifesciences approved the appointment of Mr. Umang Vohra as Chairman and Group CEO, succeeding Mr. Vivek Sharma who resigned effective April 30, 2026. The Board also approved the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' covering 2.59 crore options. These leadership transitions and incentive plans are subject to shareholder approval via postal ballot.

Read the filing ↗